Watson's Q3 profit rises, as it awaits launch of authorised generic Lipitor
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticals reported third-quarter net revenue of $1.1 billion – representing a 23% increase from a year earlier. In the quarter, the firm's global generics business performed "exceptionally well" based on strong contributions from the company's extended-release and oral contraceptive franchises in the US, stated CEO Paul Bisaro.